Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Podobne knjige/članki

• Pretreatment neutrophil‐lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor‐mutant non‐small cell lung cancer patients treated with tyrosine kinase inhibitors
  od: Sim, Sung Hoon, et al.
  Izdano: (2015)
• How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution
  od: Keam, Bhumsuk, et al.
  Izdano: (2013)
• Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
  od: Park, Sehhoon, et al.
  Izdano: (2015)
• Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor
  od: Park, Sehhoon, et al.
  Izdano: (2018)
• The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
  od: Kim, Hyungjin, et al.
  Izdano: (2017)